Neuroprotective effect of bone marrow-derived mesenchymal stem cell secretome in 6-OHDA-induced Parkinson's disease

Regen Med. 2021 Oct;16(10):915-930. doi: 10.2217/rme-2021-0018. Epub 2021 Sep 23.

Abstract

Aim: The aim of the study was to evaluate the neuroprotective effect of bone marrow stem cell secretome in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease. Materials & methods: Secretome prepared from mesenchymal stem cells of 3-month-old rats was injected daily for 7 days between days 7 and 14 after 6-OHDA administration. After 14 days, various neurobehavioral parameters were conducted. These behavioral parameters were further correlated with biochemical and molecular findings. Results & conclusion: Impaired neurobehavioral parameters and increased inflammatory, oxidative stress and apoptotic markers in the 6-OHDA group were significantly modulated by secretome-treated rats. In conclusion, mesenchymal stem cell-derived secretome could be further explored for the management of Parkinson's disease.

Keywords: 6-OHDA; Parkinson's disease; bone marrow; dopaminergic neurons; levodopa; mesenchymal stem cells; neuroprotection; secretome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow
  • Disease Models, Animal
  • Mesenchymal Stem Cells*
  • Neuroprotective Agents*
  • Oxidopamine / adverse effects
  • Parkinson Disease* / therapy
  • Rats

Substances

  • Neuroprotective Agents
  • Oxidopamine